✦ LIBER ✦

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

✍ Scribed by van de Putte, L B A

Book ID: 125455100
Publisher: BMJ Publishing Group
Year: 2004
Tongue: English
Weight: 457 KB
Volume: 63
Category: Article
ISSN: 0003-4967
DOI: 10.1136/ard.2003.013052

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness Analysis of Biologica

Cost-Effectiveness Analysis of Biological Disease-Modifying Antirheumatic Drugs in the Treatment of Russian Patients with Rheumatoid Arthritis Who Failed Previous Anti-Tnf-Alfa Therapy

✍ Ryazhenov, V.V.; Emchenko, I.V. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Efficacy of tocilizumab in patients with

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

✍ Yazici, Y.; Curtis, J. R.; Ince, A.; Baraf, H.; Malamet, R. L.; Teng, L. L.; Kav 📂 Article 📅 2011 🏛 BMJ Publishing Group 🌐 English ⚖ 301 KB

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods